Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,126 public trials 2,032 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, not recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

NCT04718883

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Peking University Cancer Hospital Beijing, Beijing Municipality, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Fujian Medical University Consonancy Hospital Fuzhou, Fujiang, China
  • Guangdong Province people hospital Guanzhou, Guangdong, China
View Trial Details
Active, not recruiting

Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia

NCT00003861

Conditions
Acute Lymphoblastic Leukemia, Acute Promyelocytic Leukemia, Hematologic Diseases, +13 more
Locations
  • Naval Medical Center - San Diego San Diego, California, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States
  • Tunnell Cancer Center at Beebe Medical Center Lewes, Delaware, United States
  • CCOP - Christiana Care Health Services Newark, Delaware, United States
View all 51 locations
View Trial Details
Active, not recruiting

Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma

NCT04613557

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • H. Lee Moffitt Cancer Center Tampa, Florida, United States
  • Nyu Langone Hospitals New York, United States
  • Universitair Ziekenhuis Antwerpen Antwerp, Belgium
  • Institut Jules Bordet Brussels, Belgium
View Trial Details
Active, not recruiting

Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL

NCT03962465

Conditions
B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +15 more
Locations
  • Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States
  • University of Virginia Charlottesville, Virginia, United States
  • VCU Massey Cancer Center Richmond, Virginia, United States
  • University of Wisconsin Madison, Wisconsin, United States
View Trial Details
Active, not recruiting

Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

NCT03948035

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Univ. Klinikum Krems Krems, Lower Austria, Austria
  • Universitätklinikum St. Pölten Sankt Pölten, Lower Austria, Austria
  • LKH-Universitätsklinikum Graz Graz, Styria, Austria
  • Medizinische Universität Innsbruck Innsbruck, Tyrol, Austria
View all 56 locations
View Trial Details
Active, not recruiting

Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

NCT04526834

Conditions
Anaplastic Large Cell Lymphoma, Diffuse Large B Cell Lymphoma, Extranodal NK/T-cell Lymphoma, +17 more
Locations
  • City of Hope Duarte, California, United States
  • Sarah Cannon Research Institute Nashville, Tennessee, United States
  • Baylor College of Medicine Houston, Texas, United States
  • The University of Texas MD Anderson Cancer Centre Houston, Texas, United States
View Trial Details

Related conditions